首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Serpinf1 |
| Uniprot No | P36955 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-418aa |
| 氨基酸序列 | QNPASPPEEGSPDPDSTGALVEEEDPFFKVPVNKLAAAVSNFGYDLYRVR SSTSPTTNVLLSPLSVATALSALSLGAEQRTESIIHRALYYDLISSPDIH GTYKELLDTVTAPQKNLKSASRIVFEKKLRIKSSFVAPLEKSYGTRPRVL TGNPRLDLQEINNWVQAQMKGKLARSTKEIPDEISILLLGVAHFKGQWVT KFDSRKTSLEDFYLDEERTVRVPMMSDPKAVLRYGLDSDLSCKIAQLPLT GSMSIIFFLPLKVTQNLTLIEESLTSEFIHDIDRELKTVQAVLTVPKLKL SYEGEVTKSLQEMKLQSLFDSPDFSKITGKPIKLTQVEHRAGFEWNEDGA GTTPSPGLQPAHLTFPLDYHLNQPFIFVLRDTDTGALLFIGKILDPRGP |
| 预测分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Serpinf1(PEDF)重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Production of recombinant human pigment epithelium-derived factor in Pichia pastoris*
**作者**：Becerra SP, et al.
**摘要**：该研究利用毕赤酵母系统高效表达重组人PEDF，验证其正确折叠及生物活性，证实其具有抑制内皮细胞迁移的强效抗血管生成特性。
2. **文献名称**：*Recombinant PEDF suppresses angiogenesis and tumor growth in a murine glioblastoma model*
**作者**：Zhang X, et al.
**摘要**：通过大肠杆菌表达重组PEDF，证明其能显著抑制胶质母细胞瘤小鼠模型中的肿瘤血管生成并诱导肿瘤细胞凋亡，提示其潜在抗肿瘤应用。
3. **文献名称**：*Neuroprotective effects of recombinant Serpinf1 in a rat model of retinal degeneration*
**作者**：Tombran-Tink J, et al.
**摘要**：研究显示，重组Serpinf1蛋白通过激活下游信号通路，显著延缓视网膜变性模型中的光感受器细胞死亡，突显其神经保护功能。
---
注：以上文献信息为示例性质，实际引用时建议通过PubMed或Web of Science核对准确标题及作者。核心研究方向涵盖重组表达策略、抗血管生成及神经保护机制。
**Background of Recombinant Serpinf1 Protein**
Serpinf1 (Serine Protease Inhibitor Family F Member 1), also known as Pigment Epithelium-Derived Factor (PEDF), is a multifunctional glycoprotein encoded by the *SERPINF1* gene. Initially identified for its role in retinal homeostasis, PEDF belongs to the non-inhibitory serpin superfamily, lacking protease-inhibitory activity but exhibiting diverse biological properties. It is widely expressed in tissues, including the eye, liver, and bone, and is secreted as a 50 kDa protein.
PEDF is best known for its potent anti-angiogenic effects, counteracting vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation. This property has linked it to therapeutic potential in diseases like age-related macular degeneration (AMD) and diabetic retinopathy. Additionally, PEDF demonstrates neurotrophic activity, supporting neuronal survival in the retina and central nervous system, making it relevant for neurodegenerative conditions such as Alzheimer’s disease.
Recombinant Serpinf1 protein is produced using expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity. The *E. coli*-derived version is cost-effective but lacks glycosylation, while mammalian systems yield glycosylated forms closer to the native protein. Structural studies reveal that PEDF’s functional domains include a heparin-binding region and a neurotrophic motif, critical for receptor interactions.
Beyond ophthalmology, recombinant Serpinf1 is explored in oncology for its tumor-suppressive roles, including induction of apoptosis and inhibition of metastasis. It also modulates extracellular matrix remodeling, influencing tissue repair and bone regeneration. However, challenges remain in optimizing its stability, delivery, and pharmacokinetics for clinical use.
In summary, recombinant Serpinf1 protein represents a promising therapeutic agent with pleiotropic functions, bridging gaps between angiogenesis regulation, neuroprotection, and cancer biology. Ongoing research aims to harness its full potential through advanced bioengineering and targeted delivery strategies.
×
